AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

Search

GlaxoSmithKline PLC

Abierto

SectorSalud

1,458 2.78

Resumen

Variación precio

24h

Actual

Mínimo

1415.5

Máximo

1462.5

Métricas clave

By Trading Economics

Ingresos

559M

501M

Ventas

105M

8.1B

P/B

Media del Sector

23.581

63.778

BPA

0.232

Rentabilidad por dividendo

4.3

Margen de beneficio

6.172

Empleados

68,629

EBITDA

-52M

1.1B

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+8.46% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.30%

2.39%

Próximas Ganancias

30 abr 2025

Fecha Próximo Dividendo

10 abr 2025

Próxima Fecha de Ex Dividendo

15 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-586M

59B

Apertura anterior

1455.22

Cierre anterior

1458

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

139 / 386 Clasificación en Healthcare

GlaxoSmithKline PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 feb 2025, 11:32 UTC

Ganancias

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5 feb 2025, 08:56 UTC

Ganancias

Correction to GSK Article

5 feb 2025, 08:24 UTC

Ganancias

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5 feb 2025, 07:43 UTC

Ganancias

GSK Expects Further Profit Growth After Beating Market Views

13 ene 2025, 07:14 UTC

Adquisiciones, fusiones, absorciones

GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion

2 abr 2025, 09:27 UTC

Acciones populares

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mar 2025, 22:29 UTC

Principales Noticias

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26 mar 2025, 19:19 UTC

Principales Noticias

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26 mar 2025, 17:39 UTC

Principales Noticias

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19 mar 2025, 14:50 UTC

Principales Noticias

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17 mar 2025, 09:00 UTC

Principales Noticias

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24 feb 2025, 07:05 UTC

Adquisiciones, fusiones, absorciones

GSK Completes Acquisition of IDRx

14 feb 2025, 11:38 UTC

Principales Noticias
Ganancias

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14 feb 2025, 11:30 UTC

Principales Noticias
Ganancias

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5 feb 2025, 15:33 UTC

Charlas de Mercado
Ganancias

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5 feb 2025, 08:38 UTC

Charlas de Mercado
Ganancias

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5 feb 2025, 07:05 UTC

Ganancias

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5 feb 2025, 07:04 UTC

Ganancias

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5 feb 2025, 07:03 UTC

Ganancias

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5 feb 2025, 07:03 UTC

Ganancias

GSK PLC Raises Mid-Term View

5 feb 2025, 07:03 UTC

Ganancias

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5 feb 2025, 07:02 UTC

Ganancias

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

5 feb 2025, 07:02 UTC

Ganancias

GSK PLC Issues GBP2B Buyback

5 feb 2025, 07:01 UTC

Ganancias

GSK PLC Declares 4Q Dividend of 16p

5 feb 2025, 07:00 UTC

Ganancias

GSK PLC 4Q Core EPS Consensus Was 20.6p

5 feb 2025, 07:00 UTC

Ganancias

GSK PLC 4Q Sales Consensus Was GBP7.83B

5 feb 2025, 07:00 UTC

Ganancias

GSK PLC 4Q Pretax Pft GBP563M

5 feb 2025, 07:00 UTC

Ganancias

GSK PLC 4Q EPS 10.0p

5 feb 2025, 07:00 UTC

Ganancias

GSK PLC 4Q Adj EPS 23.2p

5 feb 2025, 07:00 UTC

Ganancias

GSK PLC 4Q Oper Pft GBP696M

Comparación entre iguales

Cambio de precio

GlaxoSmithKline PLC Esperado

Precio Objetivo

By TipRanks

8.46% repunte

Estimación a 12 meses

Media 1,593.33 GBX  8.46%

Máximo 2,290 GBX

Mínimo 1,450 GBX

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para GlaxoSmithKline PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

12 ratings

2

Comprar

8

Mantener

2

Vender

Sentimiento

By Acuity

139 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.